Every letter we have printed

The most valuable custody artefact I have is a courier record showing a parcel held for six days at a hub in July. It explains a determination that would otherwise have looked like a manufacturing failure, and it cost nothing to obtain.

I would like the laboratory’s receipt condition printed on the report. Arrived cold, arrived warm, arrived with the seal broken — three observations, made anyway on arrival, and discarded before the document is written.

One request for the checklist. Ask whether the stability data supporting the storage statement was generated on this formulation or on the same peptide in a different one. The distinction decides whether the number applies to the vial in your hand.

Where a supplier does record temperature, ask for the file rather than the summary. A single maximum figure discards the duration, and duration above a threshold is what determines the loss.

An excipient note. Mannitol crystallises and gives a firm elegant cake with poor protection; sucrose stays amorphous and protects rather better while looking worse. Buyers judge cakes by appearance, and appearance and stability are pulling in opposite directions.

Adsorption to the vial wall is the loss mechanism nobody thinks about, and it matters most at exactly the low concentrations people prepare. Material can leave a solution without degrading at all.

Reference change value is the concept that would help most people here, and almost nobody outside laboratory medicine has heard of it. It combines analytical and biological variation into a threshold for a meaningful difference.

Nothing in a laboratory report is advice and the report itself usually says so. I would like your department to keep making the same point, because a number arrives with an air of authority that a sentence of interpretation does not, and the number is the part that gets acted on.

Rapid weight change mobilises material stored in adipose tissue, and analytes that partition there behave accordingly. Reading such a movement as new pathology rather than as redistribution is an easy error and your piece describes it well.

Buyers ask for what they have seen other buyers ask for. Where nobody has ever seen a report of a particular kind, demand for it cannot form, and the absence is self-sustaining.

There is a version of this market with a certification tier, where a supplier pays for a fuller panel and is listed separately. It has not emerged, and it is worth asking why nobody has attempted it.

The most useful outcome of this series for me has been the vocabulary. I can now ask a supplier a question that is specific enough to have an answer, which was not true a year ago, and specific questions get answered far more often than general ones.

Why did you submit only two vials for sterility testing when the whole article argues that the sample size is the problem? Two is worse than twenty by exactly the argument you make.

I teach a seminar that uses two of your pieces as set reading. Students arrive expecting advocacy and are visibly unsettled by the refusal to supply any.

Incidence figures from placebo-controlled trials should always be quoted with the placebo arm beside them, and in secondary coverage they almost never are. The difference between arms is the finding; the raw proportion is not.

Trial populations are screened, and the screening removes exactly the people most likely to experience the effects being counted. Every incidence figure in this literature is a figure for a healthier-than-average population.

The comparison a reader needs is between the rate in the study and the rate in the comparator arm, and secondary coverage almost always supplies only the first. Without the second, no statement about attribution is possible at all.

Your rule about writing down the lower of two orthogonal figures is sound and I would add the corollary. If the two agree within the repeatability of the method, you have learned something real about the material. If they disagree by three points, you have learned something real about at least one of the methods, and that is worth knowing too.

Two-dimensional liquid chromatography now exists in a form a service laboratory can afford, and it collapses the whole argument: the second separation happens on the fraction rather than on the sample. It is still a specialist purchase, but the price is falling and the case for it in this market is stronger than in most.

You list five things a purity figure cannot tell you and then say the list is not an indictment of the technique. It reads like one. If a measurement is silent on content, aggregation, sequence, isomers and microbiology, why is it the measurement this market uses at all?

You write that only one laboratory attached its chromatogram to the private buyer report. That was probably us. We started doing it five years ago because the PDF seemed incomplete without it. It costs us nothing to add — the instrument generates it automatically — and it solves exactly the dispute-resolution problem you describe. More laboratories should do it, and the reason they do not is not technical.

Emptying rate and symptom intensity correlate poorly at the individual level, which is one of the more interesting findings in the area. It means the mechanism is necessary and not sufficient, and coverage that treats them as the same thing is misleading.

Adaptation over weeks is the feature that most needs explaining and the one with the least mechanistic work behind it. Everything published addresses the acute effect, which is the part that resolves on its own.

I stopped at week six because I could not keep anything down for three days, and my prescriber told me I had not given it a fair chance. Reading your definition of dose-limiting, I think what happened was that nobody offered me the option of going back to the lower dose. It was escalate or stop.

A baseline drawn before anything changes is worth more than any single later result, because it converts every subsequent value into a delta. The people who most regret not having one are the people looking at a first abnormal result with nothing to compare it against.

The discipline your article recommends is the right one: decide what you would do differently for each result before ordering it. Anything that fails that test is generating a number that will be worried about and not acted on.

The GIP contribution remains genuinely unsettled and your piece says so, which is more than most coverage manages. Agonism and antagonism at that receptor have both been argued to produce benefit, and a mechanism that works either way round is a mechanism that has not been demonstrated.

A note on species differences that catches people out. Receptor pharmacology established in rodent tissue does not transfer cleanly, and several of the older mechanistic claims in circulation rest on preparations that were never human. Your citation practice is better than most on this point.

Air bubbles are a real volume error at these scales, because a bubble that would be trivial in a millilitre is substantial in a few hundredths. The remedy is unglamorous and the article should say it: draw slowly, hold the barrel upright, expel and re-draw.

Near misses are more informative than events and are almost never described, because nothing happened. In every other safety-critical field the near miss is the primary data source.

I gave myself a tenth of my intended dose for five weeks. I had been using insulin syringes, ran out, and used the 1 mL syringes that came with the vials, which are marked in millilitres. I did not notice because the plunger was in roughly the same place. Nobody warned me these were different scales.

The convenient reconstitution is the one that makes the arithmetic trivial rather than the one that makes the volume small. Choosing a diluent volume so that a graduation corresponds to a round figure removes an entire class of error, and it costs nothing but a moment’s thought before the needle goes in.

Absorption differs between sites, and for the long-acting molecules discussed here the difference is much less consequential than for rapid-acting insulins. The rotation advice is sound and the reason usually given for it is borrowed from a different drug class.

Reuse is discussed as a sterility question and is also a mechanical one. A needle point deforms on first use in a way that is visible under magnification, and the deformation is what causes the second use to be different.

Gauge numbering runs backwards and it catches people out constantly. A higher number is a thinner needle. A reader who assumes the number tracks the diameter will order the opposite of what they wanted, and the packaging does nothing to help.

A quibble on your dead-space figure. You give two to seven microlitres for insulin-type needles, which is right for fixed-needle syringes, but the detachable pen needle plus syringe hub combinations sold in this market are considerably worse and you should say so.

The stopper is the critical surface and the one people touch. Once a stopper has been handled, the disinfection performed before handling it is no longer relevant, and the order of operations is the whole technique.

Your worked example is correct and I would extend it. A 5 mg vial reconstituted with 2 mL gives 2.5 mg per mL, so 0.2 mL contains 0.5 mg and reads as 20 units on a hundred-unit barrel. Every step of that is division and every step of it gets skipped.

Deconvolution software is doing more work than most readers realise. It will happily produce a confident neutral mass from an envelope with two overlapping series, and the output is a single clean number with no indication that it was a judgement. Ask for the raw envelope, not the deconvoluted figure.

Monoisotopic and average mass differ by enough at peptide scale to matter, and the two are quoted interchangeably in supplier literature. For a forty-residue sequence the gap is a couple of daltons, which is exactly the size of the modification a buyer might be trying to exclude.